Guzmán Carla, Benet Marta, Pisonero-Vaquero Sandra, Moya Marta, García-Mediavilla M Victoria, Martínez-Chantar M Luz, González-Gallego Javier, Castell José Vicente, Sánchez-Campos Sonia, Jover Ramiro
Experimental Hepatology Unit, IIS Hospital La Fe, Valencia, Spain.
Biochim Biophys Acta. 2013 Apr;1831(4):803-18. doi: 10.1016/j.bbalip.2012.12.014. Epub 2013 Jan 12.
Liver fatty acid binding protein (FABP1) prevents lipotoxicity of free fatty acids and regulates fatty acid trafficking and partition. Our objective is to investigate the transcription factors controlling the human FABP1 gene and their regulation in nonalcoholic fatty liver disease (NAFLD). Adenovirus-mediated expression of multiple transcription factors in HepG2 cells and cultured human hepatocytes demonstrated that FOXA1 and PPARα are among the most effective activators of human FABP1, whereas C/EBPα is a major dominant repressor. Moreover, FOXA1 and PPARα induced re-distribution of FABP1 protein and increased cytoplasmic expression. Reporter assays demonstrated that the major basal activity of the human FABP1 promoter locates between -96 and -229bp, where C/EBPα binds to a composite DR1-C/EBP element. Mutation of this element at -123bp diminished basal reporter activity, abolished repression by C/EBPα and reduced transactivation by HNF4α. Moreover, HNF4α gene silencing by shRNA in HepG2 cells caused a significant down-regulation of FABP1 mRNA expression. FOXA1 activated the FABP1 promoter through binding to a cluster of elements between -229 and -592bp, whereas PPARα operated through a conserved proximal element at -59bp. Finally, FABP1, FOXA1 and PPARα were concomitantly repressed in animal models of NAFLD and in human nonalcoholic fatty livers, whereas C/EBPα was induced or did not change. We conclude that human FABP1 has a complex mechanism of regulation where C/EBPα displaces HNF4α and hampers activation by FOXA1 and PPARα. Alteration of expression of these transcription factors in NAFLD leads to FABP1 gen repression and could exacerbate lipotoxicity and disease progression.
肝脏脂肪酸结合蛋白(FABP1)可防止游离脂肪酸的脂毒性,并调节脂肪酸的转运和分配。我们的目标是研究控制人类FABP1基因的转录因子及其在非酒精性脂肪性肝病(NAFLD)中的调控作用。腺病毒介导的多种转录因子在HepG2细胞和培养的人肝细胞中的表达表明,FOXA1和PPARα是人类FABP1最有效的激活因子,而C/EBPα是主要的显性抑制因子。此外,FOXA1和PPARα诱导了FABP1蛋白的重新分布并增加了细胞质表达。报告基因检测表明,人类FABP1启动子的主要基础活性位于-96至-229bp之间,C/EBPα在此处与复合DR1-C/EBP元件结合。该元件在-123bp处的突变降低了基础报告基因活性,消除了C/EBPα的抑制作用,并降低了HNF4α的反式激活作用。此外,通过shRNA在HepG2细胞中沉默HNF4α基因导致FABP1 mRNA表达显著下调。FOXA1通过与-229至-592bp之间的一组元件结合来激活FABP1启动子,而PPARα则通过-59bp处的保守近端元件发挥作用。最后,在NAFLD动物模型和人类非酒精性脂肪肝中,FABP1、FOXA1和PPARα同时受到抑制,而C/EBPα则被诱导或未发生变化。我们得出结论,人类FABP1具有复杂的调控机制,其中C/EBPα取代HNF4α并阻碍FOXA1和PPARα的激活。这些转录因子在NAFLD中的表达改变导致FABP1基因抑制,并可能加剧脂毒性和疾病进展。